利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

18 条记录 (耗时 0.076 秒)

    Methods for increasing the therapeutic response to electroconvulsive therapy
    4.
    发明授权
    Methods for increasing the therapeutic response to electroconvulsive therapy 有权
    增加对电惊厥治疗的治疗反应的方法

    公开(公告)号：US07326697B2

    公开(公告)日：2008-02-05

    申请号：US10411503

    申请日：2003-04-08

    申请人： Alan F. Schatzberg ,  Joseph K. Belanoff

    发明人： Alan F. Schatzberg ,  Joseph K. Belanoff

    IPC分类号： A61K31/56

    CPC分类号： A61K31/56

    摘要： This invention generally pertains to the field of psychiatry. In particular, this invention pertains to the discovery that agents which inhibit the binding of cortisol to the glucocorticoid receptor can be used in methods of increasing the therapeutic response to electroconvulsive therapy (“ECT”).

    摘要翻译： 本发明一般涉及精神病学领域。 特别地，本发明涉及抑制皮质醇与糖皮质激素受体结合的药剂可用于增加对电惊厥治疗（ECT）的治疗反应的方法。

    Methods for treating dementia
    5.
    发明授权
    Methods for treating dementia 有权
    治疗痴呆症的方法

    公开(公告)号：US06369046B1

    公开(公告)日：2002-04-09

    申请号：US09246780

    申请日：1999-02-04

    申请人： Alan F. Schatzberg ,  Joseph K. Belanoff

    发明人： Alan F. Schatzberg ,  Joseph K. Belanoff

    IPC分类号： A61K3159

    CPC分类号： A61K31/569 ,  A61K31/00 ,  A61K31/567 ,  A61K31/575

    摘要： This invention generally pertains to the field of psychiatry. In particular, this invention pertains to the discovery that agents which inhibit the binding of cortisol to its receptors can be used in methods for treating dementia. Mifepristone, a potent glucocorticoid receptor antagonist, can be used in these methods. The invention also provides a kit for treating dementa in a human including a glucoccrticoid receptor antagonist and instructional material teaching the indications, dosage and schedule of administration of the glucocoticoid receptor antagonist.

    摘要翻译： 本发明一般涉及精神病学领域。 特别地，本发明涉及抑制皮质醇与其受体结合的药剂可用于治疗痴呆症的方法。 米非司酮是一种有效的糖皮质激素受体拮抗剂，可用于这些方法。 本发明还提供了一种治疗人类痴呆症的试剂盒，包括葡糖歧视型受体拮抗剂和教导糖皮质激素受体拮抗剂给药适应症，剂量和时间表的教学材料。

    Methods for treating psychosis associated with cocaine addiction with glucocorticoid receptor antagonists
    6.
    发明授权
    Methods for treating psychosis associated with cocaine addiction with glucocorticoid receptor antagonists 有权
    用糖皮质激素受体拮抗剂治疗与可卡因成瘾有关的精神病的方法

    公开(公告)号：US06362173B1

    公开(公告)日：2002-03-26

    申请号：US09639377

    申请日：2000-08-15

    申请人： Alan F. Schatzberg ,  Joseph K. Belanoff

    发明人： Alan F. Schatzberg ,  Joseph K. Belanoff

    IPC分类号： A61K3156

    CPC分类号： A61K31/57 ,  A61K31/00 ,  A61K31/567 ,  A61K31/569 ,  A61K31/575

    摘要： This invention generally pertains to the field of psychiatry. In particular, this invention pertains to the discovery that agents which inhibit the binding of cortisol to its receptors can be used in methods for ameliorating pathologies or conditions associated with psychosis. These pathologies or conditions include psychotic major depression, schizoaffective disorders, Alzheimer's Disease and cocaine addiction. Mifepristone, a potent glucocorticoid receptor antagonist, can be used in these methods. The invention also provides a kit for the amelioration of psychosis in a human including a glucocorticoid receptor antagonist and instructional material teaching the indications, dosage and schedule of administration of the glucocorticoid receptor antagonist.

    摘要翻译： 本发明一般涉及精神病学领域。 特别地，本发明涉及抑制皮质醇与其受体结合的药剂可用于改善与精神病有关的病状或病症的方法。 这些病理或病症包括精神病性重症抑郁症，分裂情感障碍，阿尔茨海默病和可卡因成瘾。 米非司酮是一种有效的糖皮质激素受体拮抗剂，可用于这些方法。 本发明还提供了用于改善人类精神病的试剂盒，包括糖皮质激素受体拮抗剂和教导糖皮质激素受体拮抗剂施用的适应症，剂量和时间表的教学材料。

    Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
    10.
    发明授权
    Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4 失效
    用于改善具有重要抑郁症并携带载脂蛋白E4基因的人的治疗反应的方法

    公开(公告)号：US06399310B1

    公开(公告)日：2002-06-04

    申请号：US09780512

    申请日：2001-02-12

    申请人： Greer M. Murphy, Jr. ,  Alan F. Schatzberg

    发明人： Greer M. Murphy, Jr. ,  Alan F. Schatzberg

    IPC分类号： C12Q168

    CPC分类号： C12Q1/6883 ,  C12Q2600/156

    摘要： This invention relates to methods for improving the therapeutic response of human patients with major depression by determining the apolipoprotein E genotype of a human patient and administering mirtazapine, in an amount effective to treat major depression, to those patients who are found to carry the gene for apolipoprotein E4. Also disclosed are methods for improving the therapeutic response of a human patient with major depression comprising administering mirtazapine, in an amount effective to treat major depression, to a human patient who is a carrier of the gene for apolipoprotein E4.

    摘要翻译： 本发明涉及通过确定人类患者的载脂蛋白E基因型并以有效治疗重度抑郁症的剂量给予那些被发现携带该基因的患者的米氮平，来改善患有主要抑郁症的人类患者的治疗反应的方法 载脂蛋白E4。 还公开了用于改善具有主要抑郁症的人类患者的治疗反应的方法，其包括给予作为载脂蛋白E4基因的载体的人类患者施用有效治疗主要抑郁症的量的米氮平。